Archive: May 2023
Feature Article
Blastic Plasmacytoid Dendritic Cell Neoplasm: Emerging Developments and Special Considerations for 2023
Abstract: The field of blastic plasmacytoid dendritic cell neoplasm (BPDCN) is rapidly evolving. Recent clinical developments in this ultra-rare hematologic malignancy have included the emergence of […]
Feature Article
Novel Approaches to the Treatment of Multiple Myeloma
Abstract: The treatment landscape for multiple myeloma (MM) has evolved significantly over the last decade with the approval of novel therapies and combinations in the newly […]
Advances in Hematology
Management of Antithrombin Deficiency
H&O What is antithrombin deficiency? IP Antithrombin deficiency refers to a decrease in the natural clotting inhibitor, antithrombin. Antithrombin is important because it inhibits clotting factors, […]
Ovarian Cancer
The Emerging Use of Antibody-Drug Conjugates in Ovarian Cancer
H&O Which patients with ovarian cancer are eligible for treatment with an antibody-drug conjugate (ADC)? DR The only ADC that has received US Food and Drug […]
Letter From the Editor
Letter From the Editor: How Do We Celebrate—and Survive—Increasing Survival?
As I approach my 25th year in oncology practice, I think back to when I started and the remarkable expansion since then of treatment options for […]
Advances in Drug Development
Dosing of Nivolumab in India
H&O What factors determine the appropriate dose of nivolumab? VN The dosing of any drug is determined by multiple factors. Traditionally, drug dosing is initially determined […]
Advances in LLM
Quizartinib, the Next FLT3 Inhibitor
H&O What are FMS-like tyrosine kinase 3 (FLT3) inhibitors, and how have they affected the treatment of patients with acute myeloid leukemia (AML)? JC FLT3 mutations […]